Has Ira Jacobson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $320,587 in general payments to Ira Jacobson, MD across 261 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ira Jacobson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ira Jacobson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ira Jacobson, MD

Gastroenterology · New York, NYNPI 1851488936

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $267,960 of the $320,587 with a category attached, or 83.6%. 26 manufacturers reported payments, led by GSK at 30.0% of the total. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$320,587in general payments, 2019–2025

Across 261 payments — averaging $1228.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$96K
Gilead$95K
Merck$34K
Intercept Pharmaceuticals, Inc.$15K
Novo Nordisk$15K
Madrigal Pharmaceuticals$14K
plus $51K from 20 others

$1,468,047in research payments, 2019–2025

Across 313 payments — averaging $4690.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$261K
Gilead$236K
Janssen Research & Development, LLC$215K
Intercept Pharmaceuticals, Inc.$118K
Ipsen Bioscience Inc.$113K
GSK$110K
plus $415K from 11 others

What the payments were for

Consulting fees$267,96084%
Speaking & faculty fees$20,8457%
Travel & lodging$24,7448%
Food & beverage$6,8002%
Education$2390%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	19	$96,068
Gilead	82	$95,320
Merck	21	$33,905
Intercept Pharmaceuticals, Inc.	23	$15,469
Novo Nordisk	11	$14,566
Madrigal Pharmaceuticals	19	$14,426
AbbVie	6	$9,750
Biomarin Pharmaceutical Inc.	2	$7,650
Siemens Medical Solutions USA, Inc.	5	$7,308
Modernatx, Inc.	1	$5,025
Genentech USA, Inc.	2	$4,570
F. Hoffmann-la Roche AG	5	$4,388
Alnylam Pharmaceuticals Inc.	3	$2,834
Kowa Research Institute, Inc.	4	$2,660
Janssen Global Services, LLC	2	$1,737
E.r. Squibb & Sons, L.L.C.	4	$1,389
Eli Lilly	21	$1,347
Novartis	1	$1,050
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	11	$257
Echosens North America, Inc.	1	$201
Ipsen Biopharmaceuticals, Inc	5	$163
Orphalan Inc	5	$134
Shionogi Inc	1	$117
Mirum Pharmaceuticals, Inc.	1	$100
Mallinckrodt Hospital Products Inc.	4	$96
Intra-sana Laboratories	2	$58

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Vemlidy$15,187
OCALIVA$14,867
REZDIFFRA$13,942
Epclusa$11,900
Mavyret$9,750
Livdelzi$7,736
OCREVUS$2,905
GIVLARRI$2,824
TECENTRIQ$1,665
ADVIA Immunoassay Reagents/Test Kit/Clinical Utilization$318
FibroScan$201
Wegovy$155
Mulpleta$117
Livmarli$100

How this compares

$320,587 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York →

Medicare billing

Part B allowed, 2024

$95,755

Medicare patients

439

Services billed

1,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Carvedilol	26	$173
Prednisone	14	$162

Paid to pharmacies, not to this prescriber.

Other gastroenterology in New York

David Carr LockeNew York$2M
Arthur KornbluthNew York$1.9M
Sonal KumarNew York$1M
David PoppersNew York$939K
Ellen ScherlNew York$857K
Bruce SandsNew York$810K
Jean Frederick ColombelNew York$786K
Seth GrossNew York$624K
Caterina Oneto ArayaNew York$610K
Dana LukinNew York$491K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →